Metoprolol Recall: FDA Announces Nationwide Recall of Blood Pressure Medication Over Foreign Tablets
A nationwide recall has been issued for thousands of bottles of metoprolol tartrate, a prescription medication commonly used to manage high blood pressure and certain heart conditions. The recall was initiated after concerns that some bottles may contain unidentified tablets or capsules that do not belong in the medication.
According to a U.S. Food and Drug Administration (FDA) enforcement report, pharmaceutical manufacturer Advagen Pharma Limited is recalling 3,684 bottles of metoprolol tartrate 50 mg tablets. The affected products were distributed across the United States, raising concerns among patients, pharmacies, and healthcare professionals.
The FDA classified the action as a Class II drug recall, indicating that exposure to the affected product could potentially cause temporary or medically reversible health consequences.
Here is what patients need to know about the metoprolol recall, the affected product, possible health risks, and steps to take if they have purchased or received the medication.
Why Has Metoprolol Been Recalled?
The recall was initiated because of the possible presence of foreign tablets or capsules inside bottles of metoprolol tartrate.
The FDA's enforcement report identifies the issue as the "presence of foreign tablets/capsules." However, the agency has not disclosed the identity, strength, or quantity of the unexpected medication found in the affected bottles.
The presence of unidentified medication in a prescription drug container can create potential safety concerns. Patients could unintentionally take a different medication, an incorrect dose, or a substance that may interact with their prescribed treatment.
Advagen Pharma Limited, based in East Windsor, New Jersey, voluntarily initiated the recall on October 27, 2026. The company initially notified recipients through letters.
On November 10, 2026, the FDA designated the recall as Class II.
At the time of the agency's report, no additional information was provided about how the foreign tablets or capsules entered the affected bottles.
Which Metoprolol Products Are Included in the Recall?
Patients should carefully check their prescription medication packaging to determine whether their product is included in the recall.
The recall specifically concerns metoprolol tartrate 50 mg tablets manufactured and distributed by Advagen Pharma Limited.
The affected product identification details are:
- Medication: Metoprolol tartrate tablets
- Strength: 50 mg
- Manufacturer: Advagen Pharma Limited
- Bottle quantity: 1,000 tablets
- Number of affected bottles: 3,684
- Batch number: 2611C065A1
- Expiration date: May 2028
- National Drug Code (NDC): 72888-210-00
- Distribution: Nationwide across the United States
- Recall initiation date: October 27, 2026
- FDA classification date: November 10, 2026
The National Drug Code is a product identification number that can generally be found on the medication packaging.
Patients should compare the batch number, expiration date, and NDC printed on their bottles with the information listed above. Not every metoprolol prescription is affected by this recall.
What Does an FDA Class II Drug Recall Mean?
The FDA uses different classifications to communicate the potential health risks associated with recalled products.
A Class II recall means that using or being exposed to the affected product may cause temporary or medically reversible adverse health consequences. The probability of serious adverse health consequences is considered remote.
This classification does not mean that every affected bottle will cause harm. However, the possibility of unexpected medication exposure makes it important for patients and healthcare professionals to take the recall seriously.
In this case, the FDA has not identified the foreign tablets or capsules or explained how much of the unidentified medication may be present.
The agency's report also does not state whether any patients have experienced adverse reactions linked to the affected product.
What Is Metoprolol and Why Is It Prescribed?
Metoprolol is a prescription medication belonging to a class of drugs known as beta blockers.
It works by slowing the heart rate and reducing the workload on the heart. It also helps relax blood vessels, allowing blood to flow more easily and helping lower blood pressure.
Doctors commonly prescribe metoprolol to treat several cardiovascular conditions, including:
- High blood pressure (hypertension)
- Chest pain (angina)
- Heart failure
- Certain heart-related conditions following a heart attack
The medication can help reduce the risk of complications associated with cardiovascular disease when taken as prescribed.
Metoprolol is available in different formulations and strengths. Patients should follow their individual prescription instructions and should not assume that all metoprolol products are included in the current recall.
Should Patients Stop Taking Recalled Metoprolol?
Patients who discover that they have a potentially affected bottle should contact their pharmacist or prescribing healthcare professional for specific instructions.
Importantly, patients should not suddenly discontinue metoprolol without medical advice.
According to MedlinePlus, abruptly stopping this medication can cause serious heart-related problems. Depending on the patient's medical condition, suddenly withdrawing treatment may worsen chest pain or increase cardiovascular risks.
FDA guidance also indicates that consumers can generally continue taking medications involved in Class II or Class III recalls unless the recalling company provides different instructions.
However, because this particular recall involves potentially unidentified tablets or capsules, patients should promptly seek guidance from their pharmacist or healthcare provider before making changes to their treatment.
Do not double a dose, change the prescribed schedule, or substitute another medication without professional advice.
What Are the Possible Side Effects of Metoprolol?
Like other prescription medications, metoprolol can cause side effects. Not everyone experiences them, and their severity can vary.
Some commonly reported side effects include:
- Dizziness or lightheadedness
- Tiredness or fatigue
- Diarrhea
- Dry mouth
- Skin rash
- Itching
Certain symptoms may indicate a more serious reaction and require immediate medical attention.
These include:
- Difficulty breathing
- Fainting
- Unusual swelling
- Rapid, pounding, or irregular heartbeat
Patients who experience severe or unexpected symptoms after taking medication should seek appropriate medical care.
Because the foreign tablets involved in the recall have not been identified, their potential side effects and interactions remain unknown.
What Should Patients Do If They Have an Affected Bottle?
Anyone who believes they may have received a recalled bottle of metoprolol should take several precautions.
1. Check the medication packaging.
Look for batch number 2611C065A1, expiration date May 2028, and NDC 72888-210-00.
2. Contact your pharmacist.
A pharmacist can help verify whether the medication is included in the recall and explain what steps to take.
3. Speak with your prescribing doctor.
Do not independently stop or change your treatment. Ask your healthcare provider how to maintain your blood pressure or heart condition management safely.
4. Follow the manufacturer's recall instructions.
Advagen initially notified recipients through letters. Patients and healthcare professionals should follow any applicable instructions provided by the company or their pharmacy.
5. Report suspected medication problems.
Patients, consumers, and healthcare professionals can report serious medication-related problems through the FDA's MedWatch reporting program.
How Can Patients Report Adverse Reactions?
The FDA operates MedWatch, a safety reporting program that collects information about adverse events and problems involving prescription medications and other regulated medical products.
Patients and healthcare professionals can use the program to report suspected adverse reactions, medication errors, and product quality concerns.
Reporting suspected problems helps regulators identify potential safety issues and monitor medications available to the public.
Additional information and reporting resources are available through the official FDA MedWatch website:
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
What Happens Next?
The metoprolol recall highlights the importance of medication quality control and accurate pharmaceutical packaging.
Although the FDA has classified the action as Class II, important questions remain unanswered, including the identity of the foreign tablets or capsules and how they entered the affected bottles.
The agency's enforcement report does not identify the pharmacies that received the recalled products or confirm whether patients have experienced adverse reactions.
Patients taking metoprolol should remain attentive to updates from the FDA, their pharmacies, and Advagen Pharma Limited.
For now, checking medication packaging and consulting a qualified healthcare professional are important steps for anyone who may have received an affected bottle.
Disclaimer: This article is intended for informational and educational purposes only and should not be considered medical advice. It does not replace consultation with a qualified healthcare professional. Patients should not stop, change, or adjust prescribed medication without speaking with their doctor or pharmacist. For medical emergencies, seek immediate medical attention.
Sources
- U.S. Food and Drug Administration (FDA).
- U.S. Food and Drug Administration (FDA). MedWatch: FDA Safety Information and Adverse Event Reporting Program.
- MedlinePlus. Metoprolol. U.S. National Library of Medicine.
